SONNET BioTherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells.
Sonnet BioTherapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/sonnet-biotherapeutics-inc.” connections=”true” suffix=””]
SONNET BioTherapeutics leverages a scaffold based on proprietary albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. Its proprietary TriDENT_ Discovery Platform, derived from the three core attributes, which work together for the Discovery of Enhanced Novel Therapeutics (DENT).
(1). Single-Chain Antibody (ScFV) Based. (2). Albumin Binding Domain (ABD); scFV that binds Human Serum Albumin (HSA).
(3). Recombinant Human (Hu) Proteins.